Abstract 248P
Background
Carcinoma cervix is a leading cause of cancer in Indian females where 15%–60% of the cases eventually metastasize. This is a retrospective review of outcome of metastatic carcinoma cervix patients treated in Kidwai Memorial institute, Bangalore from 2016-2018.
Methods
We retrospectively analysed our data between October 2016 and September 2018 to identify the cases of metastatic carcinoma cervix and tried to analyse their outcomes with platinum-based chemotherapy.
Results
138 cases of metastatic carcinoma cervix were identified during these 2 years. Median age was 49 years (29-73 years). 27(19.5%) patients were HIV+. 39(28.8%) were upfront metastatic & 99(71.8%) were recurrent metastatic. Most common histology was Squamous cell carcinoma, grade II (50%). Nodal recurrence was seen in 108 (78.2%) patients, with most common being pelvic lymph nodes (69.5%) followed by retroperitoneal lymphadenopathy (36.9%) & supraclavicular lymphadenopathy (19.5%). Distant recurrence seen in 93 patients (67.3%) & most common site was lung (54.3%) followed by liver(45.6%), adrenal(4.3%), bone(6.5%) & ascites(8.6%). Nodal-only recurrence was seen in 45 (32.6%) patients. 129(93.4%) patients received palliative chemotherapy as follows- Paclitaxel/Carboplatin (82.6%), Paclitaxel/Cisplatin (6.5%), Gemcitabine/Carboplatin (2.1%), Paclitaxel/Carboplatin/Bevacizumab (2.1%). Overall response rates were 32.6% (CR-4.3%). Median progression-free survival and overall survival (OS) were 6 months and 13 months, respectively.
Conclusions
Nodal-only metastasis did not show favourable outcome as compared to visceral metastasis. However, disease remains aggressive and poor survival demands further research into newer molecules & regimens.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
304P - Survival outcomes and survival predictors in recurrent and metastatic head and neck squamous cell cancer (R/M-HNSCC) patients treated with chemotherapy (CT) plus cetuximab as first-line therapy in a real-world study
Presenter: Filipa Pontes
Session: Poster display session
Resources:
Abstract
305P - A retrospective study to evaluate patient characteristics for recurrent head and neck cancer after definitive treatment
Presenter: Tetsuro Wakasugi
Session: Poster display session
Resources:
Abstract
306P - Efficacy and safety of apatinib in heavily pretreated metastatic adenocarcinoma of the head and neck
Presenter: Lin Gui
Session: Poster display session
Resources:
Abstract
307P - Lacrimal gland tumours: Clinical and epidemiological patterns in the United States
Presenter: Mahmoud KhalafAllah
Session: Poster display session
Resources:
Abstract
308P - Dental prophylaxis and 5-fluorouracil related oral mucositis in head and neck cancer patients: A population-based cohort study
Presenter: Yi-Fang Huang
Session: Poster display session
Resources:
Abstract
309P - Evaluation of a pharmacist-led opioid de-escalation (PLODE) program after chemoradiotherapy completion in head and neck cancer patients
Presenter: Ai Horinouchi
Session: Poster display session
Resources:
Abstract
310P - Laser and PDT for the oral leukoplakia
Presenter: Sadykov Rasul
Session: Poster display session
Resources:
Abstract
311P - Incidence of thyroid carcinoma in the Philippines: A retrospective study from a tertiary university hospital
Presenter: Priscilla Caguioa
Session: Poster display session
Resources:
Abstract
312P - Oral health disparities among privileged and underprivileged tribes of south India - A study on precancerous oral lesions prevalence
Presenter: Shanavas Palliyal
Session: Poster display session
Resources:
Abstract
313P - Immunotherapy application for advanced cancers: One institution experiences since 2016 to 2019
Presenter: Jo Pai Chen
Session: Poster display session
Resources:
Abstract